Autism and the synapse: Emerging mechanisms and mechanism-based therapies

Current Opinion in Neurology

Volumn 28, Issue 2, 2015, Pages 91-102

  Ebrahimi Fakhari, Darius ^a,b   Sahin, Mustafa ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Angelman syndrome; Autism spectrum disorder; Clinical trials; Fragile X syndrome; Genetics; Intellectual disability; Neurobiology; Phelan McDermid syndrome; SHANK3; Synapse; Tuberous sclerosis complex

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ACAMPROSATE; ARBACLOFEN; ARIPIPRAZOLE; BASIMGLURANT; CITALOPRAM; DONEPEZIL; EVEROLIMUS; GANAXOLONE; LEVODOPA; MAVOGLURANT; MECAMYLAMINE; MEMANTINE; MINOCYCLINE; RAPAMYCIN; RILUZOLE; SCAFFOLD PROTEIN; SOMATOMEDIN C;

AUTISM; DEVELOPMENTAL DISORDER; FRAGILE X SYNDROME; GENE MUTATION; GENETIC VARIABILITY; HAPPY PUPPET SYNDROME; NERVE CELL PLASTICITY; OBSESSIVE COMPULSIVE DISORDER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHELAN MCDERMID SYNDROME; PLURIPOTENT STEM CELL; POSTSYNAPTIC POTENTIAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; QUALITY CONTROL; REVIEW; SYNAPSE; TUBEROUS SCLEROSIS; ANIMAL; AUTISTIC DISORDER; DISEASE MODEL; GENETIC PREDISPOSITION; GENETICS; HUMAN;

ANIMALS; AUTISTIC DISORDER; DISEASE MODELS, ANIMAL; FRAGILE X SYNDROME; GENETIC PREDISPOSITION TO DISEASE; HUMANS; SYNAPSES; TUBEROUS SCLEROSIS;

EID: 84926336177     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000186     Document Type: Review

References (107)

1. Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet 2014; 383:896-910.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
3. De Rubeis S, He X, Goldberg AP, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 2014; 515:209-215.
4. Pinto D, Delaby E, Merico D, et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am J Hum Genet 2014; 94:677-694.
5. Santini E, Huynh TN, MacAskill AF, et al. Exaggerated translation causes synaptic and behavioural aberrations associated with autism. Nature 2013; 493:411-415.
6. Wang T, Bray SM, Warren ST. New perspectives on the biology of fragile X syndrome. Curr Opin Genet Dev 2012; 22:256-263.
7. Rooms L, Kooy RF. Advances in understanding fragile X syndrome and related disorders. Curr Opin Pediatr 2011; 23:601-606.
8. Bhakar AL, Dolen G, Bear MF. The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci 2012; 35:417-443.
9. Hernandez RN, Feinberg RL, Vaurio R, et al. Autism spectrum disorder in fragile X syndrome: A longitudinal evaluation. Am J Med Genet A 2009; 149A:1125-1137.
10. Williams TA, Porter MA, Langdon R. Social approach and emotion recognition in fragile X syndrome. Am J Intellect Dev Disabil 2014; 119:133-150.
11. McDuffie A, Thurman AJ, Hagerman RJ, Abbeduto L. Symptoms of autism in males with fragile X syndrome: A comparison to nonsyndromic ASD using current ADI-R scores. J Autism Dev Disord 2014. [Epub ahead of print]. doi: 10.1007/s10803-013-2013-6.
12. Darnell JC, Van Driesche SJ, Zhang C, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011; 146:247-261.
13. Santoro MR, Bray SM, Warren ST. Molecular mechanisms of fragile X syndrome: A twenty-year perspective. Annu Rev Pathol 2012; 7:219-245.
14. Irwin SA, Galvez R, Greenough WT. Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex 2000; 10:1038-1044.
15. Grossman AW, Aldridge GM, Weiler IJ, Greenough WT. Local protein synthesis and spine morphogenesis: Fragile X syndrome and beyond. J Neurosci 2006; 26:7151-7155.
16. Patel AB, Loerwald KW, Huber KM, Gibson JR. Postsynaptic FMRP promotes the pruning of cell-to-cell connections among pyramidal neurons in the L5A neocortical network. J Neurosci 2014; 34:3413-3418.
17. Padmashri R, Reiner BC, Suresh A, et al. Altered structural and functional synaptic plasticity with motor skill learning in a mouse model of fragile X syndrome. J Neurosci 2013; 33:19715-19723.
18. Krueger DD, Bear MF. Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med 2011; 62:411-429.
19. Lee HY, Jan LY. Fragile X syndrome: mechanistic insights and therapeutic avenues regarding the role of potassium channels. Curr Opin Neurobiol 2012; 22:887-894.
20. Aschrafi A, Cunningham BA, Edelman GM, Vanderklish PW. The fragile X mental retardation protein and group I metabotropic glutamate receptors regulate levels of mRNA granules in brain. Proc Natl Acad Sci USA 2005; 102:2180-2185.
21. Osterweil EK, Krueger DD, Reinhold K, Bear MF. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J Neurosci 2010; 30:15616-15627.
22. Dolen G, Osterweil E, Rao BS, et al. Correction of fragile X syndrome in mice. Neuron 2007; 56:955-962.
23. Silverman JL, Smith DG, Rizzo SJ, et al. Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci Transl Med 2012; 4:131ra151.
24. Jacquemont S, Berry-Kravis E, Hagerman R, et al. The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014; 231:1237-1250.
25. Scharf SH, Jaeschke G, Wettstein JG, Lindemann L.Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome. CurrOpin Pharmacol 2014; 20:124-134.
26. Wang H, Wu LJ, Kim SS, et al. FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron 2008; 59:634-647.
27. Paul K, Venkitaramani DV, Cox CL. Dampened dopamine-mediated neuromodulation in prefrontal cortex of fragileX mice. J Physiol 2013; 591:1133-1143.
28. Wang H, Kim SS, Zhuo M. Roles of fragile X mental retardation protein in dopaminergic stimulation-induced synapse-associated protein synthesis and subsequent alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-4-propionate (AMPA) receptor internalization. J Biol Chem 2010; 285:21888-21901.
29. Centonze D, Rossi S,Mercaldo V, et al. Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. Biol Psychiatry 2008; 63:963-973.
30. Curia G, Papouin T, Seguela P, Avoli M. Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome. Cereb Cortex 2009; 19:1515-1520.
31. Erickson CA, Stigler KA, Wink LK, et al. A prospective open-label study of aripiprazole in fragile X syndrome. Psychopharmacology (Berl) 2011; 216:85-90.
32. Lim CS, Hoang ET, Viar KE, et al. Pharmacological rescue of Ras signaling, GluA1-dependent synaptic plasticity, and learning deficits in a fragile X model. Genes Dev 2014; 28:273-289.
33. D'Hulst C, De Geest N, Reeve SP, et al. Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res 2006; 1121:238-245.
34. Adusei DC, Pacey LK, Chen D, Hampson DR. Early developmental alterations in GABAergic protein expression in fragile X knockout mice. Neuropharmacology 2010; 59:167-171.
35. Deng PY, Rotman Z, Blundon JA, et al. FMRP regulates neurotransmitter release and synaptic information transmission by modulating action potential duration via BK channels. Neuron 2013; 77:696-711.
36. Lipton JO, Sahin M. The neurology of mTOR. Neuron 2014; 84:275-291.
37. Sharma A, Hoeffer CA, Takayasu Y, et al. Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 2010; 30:694-702.
38. Amiri A, Sanchez-Ortiz E, Cho W, et al. Analysis of FMR1 deletion in a subpopulation of postmitotic neurons in mouse cortex and hippocampus. Autism Res 2014; 7:60-71.
39. Kumari D, Bhattacharya A, Nadel J, et al. Identification of fragile X syndrome specific molecular markers in human fibroblasts: A useful model to test the efficacy of therapeutic drugs. Hum Mutat 2014; 35:1485-1494.
40. Bhattacharya A, Kaphzan H, Alvarez-Dieppa AC, et al. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 2012; 76:325-337.
41. Gross C, Nakamoto M, Yao X, et al. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J Neurosci 2010; 30:10624-10638.
42. Osterweil EK, Chuang SC, Chubykin AA, et al. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 2013; 77:243-250.
43. McBride SM, Choi CH, Wang Y, et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 2005; 45:753-764.
44. King MK, Jope RS. Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome. Genes Brain Behav 2013; 12:723-731.
45. Liu ZH, Huang T, Smith CB. Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome. Neurobiol Dis 2012; 45:1145-1152.
46. Choi CH, Schoenfeld BP, Bell AJ, et al. Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment. Brain Res 2011; 1380:106-119.
47. Min WW, Yuskaitis CJ, Yan Q, et al. Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology 2009; 56:463-472.
48. Berry-Kravis E, Sumis A, Hervey C, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr 2008; 29:293-302.
49. Northrup H, Krueger DA. International Tuberous Sclerosis Complex Consensus G: Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49:243-254.
50. de Vries PJ, Whittemore VH, Leclezio L, et al. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND checklist. Pediatr Neurol 2015; 52:25-35.
51. Crino PB. Evolving neurobiology of tuberous sclerosis complex. Acta Neuropathol 2013; 125:317-332.
52. Dibble CC, Elis W, Menon S, et al. TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell 2012; 47:535-546.
53. Reith RM, McKenna J, WuH, et al. Loss of Tsc2 in Purkinje cells is associated with autistic-like behavior in a mouse model of tuberous sclerosis complex. Neurobiol Dis 2013; 51:93-103.
54. Tsai PT, Hull C, Chu Y, et al. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. Nature 2012; 488:647-651.
55. Ehninger D, Han S, Shilyansky C, et al. Reversal of learning deficits in a Tsc2/-mouse model of tuberous sclerosis. Nat Med 2008; 14:843-848.
56. Goorden SM, van Woerden GM, van der Weerd L, et al. Cognitive deficits in Tsc1/-mice in the absence of cerebral lesions and seizures. Ann Neurol 2007; 62:648-655.
57. Tavazoie SF, Alvarez VA, Ridenour DA, et al. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat Neurosci 2005; 8:1727-1734.
58. Yasuda S, Sugiura H, Katsurabayashi S, et al. Activation of Rheb, but not of mTORC1, impairs spine synapse morphogenesis in tuberous sclerosis complex. Sci Rep 2014; 4:5155.
59. Choi YJ, Di Nardo A, Kramvis I, et al. Tuberous sclerosis complex proteins control axon formation. Genes Dev 2008; 22:2485-2495.
60. Nie D, Di Nardo A, Han JM, et al. Tsc2-Rheb signaling regulates EphAmediated axon guidance. Nat Neurosci 2010; 13:163-172.
61. Tang G, Gudsnuk K, Kuo SH, et al. Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron 2014; 83:1131-1143.
62. Ebrahimi-Fakhari D, Wahlster L, Hoffmann GF, Kolker S. Emerging role of autophagy in pediatric neurodegenerative and neurometabolic diseases. Pediatr Res 2014; 75:217-226.
63. Di Nardo A, Wertz MH, Kwiatkowski E, et al. Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1. Hum Mol Genet 2014; 23:3865-3874.
64. Ebrahimi-Fakhari D, Wahlster L, McLean PJ. Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathol 2012; 124:153-172.
65. Tang SJ, Reis G, Kang H, et al. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci USA 2002; 99:467-472.
66. Stoica L, Zhu PJ, Huang W, et al. Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage. Proc Natl Acad Sci USA 2011; 108:3791-3796.
67. Zeng LH, Ouyang Y, Gazit V, et al. Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. Neurobiol Dis 2007; 28:184-196.
68. Bateup HS, Takasaki KT, Saulnier JL, et al. Loss of Tsc1 in vivo impairs hippocampal mGluR-LTD and increases excitatory synaptic function. J Neurosci 2011; 31:8862-8869.
69. Bateup HS, Johnson CA, Denefrio CL, et al. Excitatory/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis. Neuron 2013; 78:510-522.
70. Krueger DA, Northrup H. International Tuberous Sclerosis Complex Consensus G: Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49:255-265.
71. Williams CA, Beaudet AL, Clayton-Smith J, et al. Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med Genet A 2006; 140:413-418.
72. Bonati MT, Russo S, Finelli P, et al. Evaluation of autism traits in Angelman syndrome: A resource to unfold autism genes. Neurogenetics 2007; 8:169-178.
73. Sadikovic B, Fernandes P, Zhang VW, et al. Mutation update for UBE3A variants in Angelman syndrome. Hum Mutat 2014; 35:1407-1417.
74. Jiang YH, Armstrong D, Albrecht U, et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron 1998; 21:799-811.
75. Yashiro K, Riday TT, Condon KH, et al. Ube3a is required for experiencedependent maturation of the neocortex. Nat Neurosci 2009; 12:777-783.
76. Sato M, Stryker MP. Genomic imprinting of experience-dependent cortical plasticity by the ubiquitin ligase gene Ube3a. Proc Natl Acad Sci USA 2010; 107:5611-5616.
77. Wallace ML, Burette AC, Weinberg RJ, Philpot BD. Maternal loss of Ube3a produces an excitatory/inhibitory imbalance through neuron type-specific synaptic defects. Neuron 2012; 74:793-800.
78. Hayrapetyan V, Castro S, Sukharnikova T, et al. Region-specific impairments in striatal synaptic transmission and impaired instrumental learning in a mouse model of Angelman syndrome. Eur J Neurosci 2014; 39:1018-1025.
79. Greer PL, Hanayama R, Bloodgood BL, et al. The Angelman syndrome protein Ube3A regulates synapse development by ubiquitinating arc. Cell 2010; 140:704-716.
80. Kuhnle S, Mothes B, Matentzoglu K, Scheffner M. Role of the ubiquitin ligase E6AP/UBE3A in controlling levels of the synaptic protein Arc. Proc Natl Acad Sci USA 2013; 110:8888-8893.
81. Cao C, Rioult-Pedotti MS, Migani P, et al. Impairment of TrkB-PSD-95 signaling in Angelman syndrome. PLoS Biol 2013; 11:e1001478.
82. Pignatelli M, Piccinin S, Molinaro G, et al. Changes in mGlu5 receptordependent synaptic plasticity and coupling to homer proteins in the hippocampus of Ube3A hemizygous mice modeling Angelman syndrome. J Neurosci 2014; 34:4558-4566.
83. Dindot SV, Antalffy BA, Bhattacharjee MB, Beaudet AL. The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology. Hum Mol Genet 2008; 17:111-118.
84. Miao S, Chen R, Ye J, et al. The Angelman syndrome protein Ube3a is required for polarized dendrite morphogenesis in pyramidal neurons. J Neurosci 2013; 33:327-333.
85. Kaphzan H, Buffington SA, Jung JI, et al. Alterations in intrinsic membrane properties and the axon initial segment in a mouse model of Angelman syndrome. J Neurosci 2011; 31:17637-17648.
86. Kaphzan H, Buffington SA, Ramaraj AB, et al. Genetic reduction of the alpha1 subunit of Na/K-ATPase corrects multiple hippocampal phenotypes in Angelman syndrome. Cell Rep 2013; 4:405-412.
87. Sheng M, Kim E. The postsynaptic organization of synapses. Cold Spring Harb Perspect Biol 2011; 3.
88. Ting JT, Peca J, Feng G. Functional consequences of mutations in postsynaptic scaffolding proteins and relevance to psychiatric disorders. Annu Rev Neurosci 2012; 35:49-71.
89. Sarasua SM, Boccuto L, Sharp JL, et al. Clinical and genomic evaluation of 201 patients with Phelan-McDermid syndrome. Hum Genet 2014; 133:847-859.
90. Boccuto L, Lauri M, Sarasua SM, et al. Prevalence of SHANK3 variants in patients with different subtypes of autism spectrum disorders. Eur J Hum Genet 2013; 21:310-316.
91. Durand CM, Betancur C, Boeckers TM, et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 2007; 39:25-27.
92. Moessner R, Marshall CR, Sutcliffe JS, et al. Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet 2007; 81:1289-1297.
93. Leblond CS, Nava C, Polge A, et al. Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: A gradient of severity in cognitive impairments. PLoS Genet 2014; 10:e1004580.
94. Sheng M, Kim E. The Shank family of scaffold proteins. J Cell Sci 2000; 113:1851-1856.
95. Bockers TM, Mameza MG, Kreutz MR, et al. Synaptic scaffolding proteins in rat brain. Ankyrin repeats of the multidomain Shank protein family interact with the cytoskeletal protein alpha-fodrin. J Biol Chem 2001; 276:40104-40112.
96. Sala C, Roussignol G, Meldolesi J, Fagni L. Key role of the postsynaptic density scaffold proteins Shank and Homer in the functional architecture of Ca2 homeostasis at dendritic spines in hippocampal neurons. J Neurosci 2005; 25:4587-4592.
97. Verpelli C, Dvoretskova E, Vicidomini C, et al. Importance of Shank3 protein in regulating metabotropic glutamate receptor 5 (mGluR5) expression and signaling at synapses. J Biol Chem 2011; 286:34839-34850.
98. Jiang YH, Ehlers MD. Modeling autism by SHANK gene mutations in mice. Neuron 2013; 78:8-27.
99. Bozdagi O, Sakurai T, Papapetrou D, et al. Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol Autism 2010; 1:15.
100. Peca J, Feliciano C, Ting JT, et al. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 2011; 472:437-442.
101. Wang X, McCoy PA, Rodriguiz RM, et al. Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. Hum Mol Genet 2011; 20:3093-3108.
102. Kouser M, Speed HE, Dewey CM, et al. Loss of predominant Shank3 isoforms results in hippocampus-dependent impairments in behavior and synaptic transmission. J Neurosci 2013; 33:18448-18468.
103. Yang M, Bozdagi O, Scattoni ML, et al. Reduced excitatory neurotransmission and mild autism-relevant phenotypes in adolescent Shank3 null mutant mice. J Neurosci 2012; 32:6525-6541.
104. Raynaud F, Janossy A, Dahl J, et al. Shank3-Rich2 interaction regulates AMPA receptor recycling and synaptic long-term potentiation. J Neurosci 2013; 33:9699-9715.
105. Duffney LJ, Wei J, Cheng J, et al. Shank3 deficiency induces NMDA receptor hypofunction via an actin-dependent mechanism. J Neurosci 2013; 33:15767-15778.
106. Grabrucker S, Jannetti L, Eckert M, et al. Zinc deficiency dysregulates the synaptic ProSAP/Shank scaffold and might contribute to autism spectrum disorders. Brain 2014; 137:137-152.
107. Shcheglovitov A, Shcheglovitova O, Yazawa M, et al. SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. Nature 2013; 503:267-271.